Form 4: Director Susan Benton Receives Opus Genetics Stock Grant

Opus Genetics director Susan Benton was granted 24,367 restricted stock units as part of an equity compensation plan.

Summary

• Director Susan Benton acquired 24,367 shares of common stock in Opus Genetics, Inc. (IRD).
• The transaction occurred on April 20, 2026.
• The shares were granted as restricted stock units (RSUs) with a price of $0.
• Following this transaction, Susan Benton's total beneficial ownership increased to 243,894 shares.
• The RSUs vest on the earlier of the one-year anniversary of the grant date or the day prior to the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries neutral sentiment for the stock price.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Increase in total beneficial ownership by a member of the board.

Negatives

• Dilutive effect of new equity grants on existing shareholders.

Risks

• Vesting is subject to the Reporting Person's continuing service through the vesting date.

Future Outlook

The RSU grant is subject to a one-year vesting schedule, contingent upon the director's continued service to the company.

Management Comments

• The grant represents restricted stock units which vest upon the earlier of the one-year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure long-term alignment between board members and company performance.

Comparison to Industry Standards

• The use of RSU grants for board compensation is consistent with standard practices for small-cap biotechnology firms.
• The vesting period of one year is typical for director equity compensation in the life sciences industry.

Stakeholder Impact

• Shareholders may experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of the 24,367 restricted stock units on or before April 20, 2027.

Key Dates

Keywords

Opus Genetics, IRD, Form 4, Insider Trading, Equity Compensation, Director Stock Grant